Scarica l'app Stockscreener
7.06
3.98%
0.27
Dopo l'orario di chiusura:
7.03
-0.03
-0.42%
Precedente Chiudi:
$6.79
Aprire:
$6.91
Volume 24 ore:
33,647
Relative Volume:
0.55
Capitalizzazione di mercato:
$259.18M
Reddito:
$5.20M
Utile/perdita netta:
$-282.61M
Rapporto P/E:
-0.9093
EPS:
-7.764
Flusso di cassa netto:
$-24.47M
1 W Prestazione:
-6.61%
1M Prestazione:
-12.30%
6M Prestazione:
+24.73%
1 anno Prestazione:
+279.57%
Intervallo 1D:
$6.76
$7.15
Intervallo di 1 settimana:
$6.3701
$8.045
Portata 52W:
$1.75
$16.34
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Nome
Armata Pharmaceuticals Inc
Settore
Industria
Telefono
310-655-2928
Indirizzo
4503 Glencoe Avenue, Marina del Rey, CA
Compare ARMP vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
7.06 | 253.67M | 5.20M | -282.61M | -24.47M | -7.764 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-06-19 | Iniziato | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Borsa (ARMP) Ultime notizie
Armata Pharmaceuticals (ARMP) Edges Lower Amid Sector Pressure – Key Levels in FocusPost-Earnings Moves - newsline.com
ARMATA PHARMACEUTICALS INC (ARMP) Stock Chart - ChartMill
Armata Pharmaceuticals (ARMP) Slips 3.6% as Stock Tests Key Support LevelsPCR Mean Reversion - newsline.com
Armata Pharmaceuticals Slips 2.47% as Bears Test Support Near $7.12Mid Cap Momentum - newsline.com
Armata Pharmaceuticals (ARMP) Climbs 3.62% – Testing Key Resistance Near $8.26Fibonacci Arc - newsline.com
Armata Pharmaceuticals Inc. (ARMP) Q1 2026 Earnings: Significant Earnings Miss Reflects Pre-Revenue Development StageEarnings Cycle Report - newsline.com
Armata Pharmaceuticals (ARMP) price target increased by 16.67% to 17.85 - MSN
Armata Pharmaceuticals (ARMP) Shows Modest Uptick as Stock Holds Above Key SupportRectangle Pattern - The Legal Advocate
Armata Pharmaceuticals Q1 2026 Earnings: Deep EPS Miss Masks Strategic Progress, Stock RisesProfitability Analysis - newsline.com
Armata Pharmaceuticals (ARMP) Q1 2026 Earnings: Massive EPS Miss as Pre-Revenue Biotech Struggles with Costs - newsline.com
Armata Pharmaceuticals Q1 2026 Earnings: Significant EPS Miss but Stock Rises on Pipeline ProgressFinal Results - Newser
Why Is Armata Pharmaceuticals, Inc. (ARMP) Stock Down Today? - Meyka
Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update - GuruFocus
Armata Pharmaceuticals 1Q Loss/Shr $3.16 >ARMP - Moomoo
H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $15 - Moomoo
ARMP: Armata Reports Increased Revenue and Focuses on Phase 3 Tr - GuruFocus
Armata Pharmaceuticals (ARMP) Q1 2026: EPS -3.16 Misses Est. -0. - GuruFocus
Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update - TradingView
Armata Secures New Loan Amid Wider Quarterly Loss - TipRanks
Armata Pharmaceuticals (ARMP) now 82.7% owned by Innoviva after new loan - Stock Titan
Armata Pharmaceuticals, Inc. 1Q 2026: Revenue $789K, EPS ($3.16) — 10-Q Summary - TradingView
Armata (NYSE: ARMP) loss, debt surge and Phase 3 bacteremia trial plan - Stock Titan
Armata Pharma Entered Into Secured Credit Agreement With Innoviva for $25 M Maturing in 2029 >ARMP - Moomoo
Press Release: Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update - Moomoo
ARMP Technical Analysis | Trend, Signals & Chart Patterns | ARMATA PHARMACEUTICALS INC (NYSEARCA:ARMP) - ChartMill
JonesTrading Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $20 - Moomoo
FDA grants fast track status to Armata’s bacterial infection drug By Investing.com - Investing.com India
Armata Gains FDA Fast Track for AP-SA02 Therapy - TipRanks
FDA grants fast track status to Armata’s bacterial infection drug - Investing.com India
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 - PR Newswire
MSN Money - MSN
The industry tailwinds powering Armata (ARMP) growth (Underperforming) 2026-05-05Continuation Signals - newser.com
Study maps phage in Armata’s treatment candidate for lung infections - Stock Titan
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology" - marketscreener.com
ARMP Forecast, Price Target & Analyst Ratings | ARMATA PHARMACEUTICALS INC (NYSEARCA:ARMP) - ChartMill
Armata Pharmaceuticals (ARMP) director receives 51,280 stock options at $12.92 - Stock Titan
Director Daniel Gilmer reported as insider at Armata Pharmaceuticals (ARMP) - Stock Titan
Armata Pharmaceuticals : 2026 Annual Meeting Proxy - marketscreener.com
[ARS] Armata Pharmaceuticals, Inc. SEC Filing - Stock Titan
Armata Pharmaceuticals (NASDAQ: ARMP) 2026 proxy details pay, control and going concern risk - Stock Titan
Pfizer Inc. (PFE)Senior Commercial Leader Daniel B. Gilmer, Ph.D. Appointed to Armata Pharmaceuticals Board of DirectorsCertified Trade Ideas - newser.com
Armata Pharmaceuticals Appoints Pfizer Executive Daniel B. Gilmer, Ph.D. to Board to Advance Bacteriophage Therapeutics Commercialization 1 - Minichart
Armata Pharmaceuticals Adds Pfizer Executive to Board of Directors - TipRanks
Armata Pharmaceuticals adds Pfizer executive to board - Investing.com
Arm appoints Dr. Daniel Gilmer to Board effective April 24, 2026 - TradingView
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors – Company AnnouncementFT.com - Financial Times
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
ARMP (Armata Pharmaceuticals Inc.) Q4 2025 EPS drastically misses analyst estimates, sending its shares down 6.37% today.Geographic Trends - Xã Thanh Hà
ARMP (Armata Pharmaceuticals Inc.) falls 5.64% as drastically wider than expected Q4 2025 net loss spooks investors.Retail Trader Ideas - UBND thành phố Hải Phòng
Armata Pharmaceuticals Inc Azioni (ARMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):